We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Ypsomed Holding AG (YPSN) CHF11.60

Sell:130.00 CHF Buy:137.00 CHF Change: 5.00 CHF (3.86%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:130.00 CHF
Buy:137.00 CHF
Change: 5.00 CHF (3.86%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:130.00 CHF
Buy:137.00 CHF
Change: 5.00 CHF (3.86%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.

Contact details

Brunnmattstrasse 6
+41 (34) 4244111

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
1.77 billion CHF
Shares in issue:
13.65 million
Health Care Supplies
SIX Swiss Exchange
Swiss Franc
Swiss All Share Index

Key personnel

  • Simon Michel
    Chief Executive Officer
  • Niklaus Ramseier
    Chief Financial Officer
  • Frank Mengis
    Chief Operating Officer
  • Beat Maurer
    Senior Vice President - Legal and Intellectual Property, Secretary of the Board of Directors
  • Michael Zaugg
    Senior Vice President of Human Resources
  • Ulrike Bauer
    Senior Vice President of Delivery Systems
  • Sebastien Delarive
    Senior Vice President - Diabetes Care
  • Hans Lehmann
    Senior Vice President - Technology

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.